Latest news with #AndrewYates
Associated Press
30-06-2025
- Business
- Associated Press
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced favorable results from its first-in-human study evaluating ART26.12, a novel inhibitor of Fatty Acid Binding Protein 5 (FABP5). The results affirm the promising safety and pharmacokinetic (PK) profile previously observed in preclinical studies. Inhibiting FABP5 represents a unique mechanism of action with ART26.12 standing out as a first-in-class candidate in the field of pain management. The Phase 1 Single Ascending Dose (SAD) study was designed to assess the safety, tolerability, and pharmacokinetics of ART26.12 in healthy volunteers. The SAD study enrolled 49 subjects. The key findings include: Andrew Yates, Ph.D., Senior Vice President and Chief Scientific Officer at Artelo, commented, 'We are greatly encouraged with the results of the SAD study with our lead FABP5 inhibitor and we are particularly pleased to observe that the safety and PK profile that had been generated from ART26.12's non-clinical studies translated well to the human experience.' ART26.12 is the first orally administered, selective, and peripherally restricted FABP5 inhibitor to enter human clinical evaluation. By targeting FABP5, ART26.12 modulates endogenous lipid signaling molecules that exert analgesic effects through established pathways, including TRPV1, PPAR alpha, and cannabinoid receptors, with additional mechanisms such as Nav1.8 under investigation. The chronic pain therapeutics market exceeded $97 billion globally in 2023 and is expected to surpass $159 billion by 20301, driven by the increasing prevalence of conditions such as neuropathic pain, arthritis, and fibromyalgia. Despite the scale of the market, innovation remains sparse—particularly for non-opioid therapies. As part of the U.S Food and Drug Administration's Overdose Prevention Framework, the Agency has issued draft guidance aimed at encouraging the development of non-opioid analgesics for pain. ART26.12 is positioned to fill this gap with an innovative mechanism of action and favorable safety profile. A Multiple Ascending Dose study to further evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year. About ART26.12 ART26.12, Artelo's lead FABP5 inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in several pathologies. In addition to ART26.12 in CIPN, Artelo's extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, anxiety disorders, and psoriasis. ART26.12 has been included in Helping to End Addiction Long-term® (HEAL) Initiative's Preclinical Screening Platform for Pain program of the U.S. National Institutes of Health. The HEAL program is dedicated to advancing non-opioid solutions to pain and curbing opioid use disorder. 1 About Artelo Biosciences Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at and X: @ArteloBio. Forward-Looking StatementsInvestor Relations Contact: Crescendo Communications, LLC Tel: 212-671-1020 Email: [email protected]
Herald Sun
17-06-2025
- Business
- Herald Sun
KPMG Australia hires new partners in Melbourne, Sydney, Brisbane, Perth, Canberra
Don't miss out on the headlines from Business. Followed categories will be added to My News. Here is KPMG's class of 2025. The promoted ranks include 18 partners in consulting, 17 in enterprise, 11 in each of audit and assurance, and tax and legal, 8 for deal advisory and infrastructure, and rounding out the list is office of the general counsel, clients and markets, and deputy chief financial officer. 'Reflecting the balance in our business, all divisions of our firm appointed new partners, with Consulting and KPMG Enterprise, which serves the mid-market and family offices of Australia, investing most heavily,' chief executive Andrew Yates said. 'For Consulting, this was primarily an expansion of our technology and transformation capability. For KPMG Enterprise, double-digit revenue growth drove the increase. 'We also made significant investment in our heritage businesses of Audit, Tax and Deal Advisory. 'Pleasingly, the majority of this year's new partners stem from internal promotions, reflecting our focus on leadership development and building career paths at the firm.' Originally published as KPMG's 70 new partners for 2025 named and listed by division
Dublin Live
12-05-2025
- Business
- Dublin Live
Bus Eireann confirms additional Dublin Airport services including new midnight bus
Our community members are treated to special offers, promotions and adverts from us and our partners. You can check out at any time. More info Bus Eireann has confirmed additional services on the Expressway 32 route which serves Dublin Airport. The improved timetable will come into effect on 25th May 2025 and "has been designed to provide more frequent and punctual travel for all Route 32 customers". Bus Eireann said passengers will see significant benefits, as the improved schedule will better reflect traffic conditions, ensuring more consistent arrival and departure times. The timetable change will see an increase from 10 to 12 daily return services on Route 32 which serves key stops at Busáras, Dublin Airport, Ardee, Monaghan, Omagh and Lifford before arriving at Letterkenny Bus Station. It will also see the introduction of a new midnight departure from Letterkenny, offering customers the chance to avail of early flights from Dublin Airport – as well as a new late night departure from Dublin at 00:15 providing a convenient option for those travelling after evening events in the city. Head of Expressway, Andrew Yates said: 'The upcoming Route 32 timetable changes are designed to significantly improve service punctuality, enhance customer experience, and most importantly increase service frequency by 20%. This will enable us to add almost 1,500 weekly passenger journeys and is in response to the growing demand on this corridor. "These improved timetables offer better punctuality along key segments of Route 32, including arrivals into Dublin Airport. Departure times have been restructured to provide for customers during the busiest periods, ensuring availability when it is needed most. The first morning departure from Dublin has been amended slightly to support improved punctuality across the timetable. All of the changes introduced have been customer centred and driven by feedback to ensure smoother, more reliable journeys. "We advise all customers to check the new timetables on to familiarise themselves with changes to departure times. For example, the previous 22:00 departure from Dublin Airport will instead depart at 22:30, better accommodating passengers arriving on late evening flights. "Expressway remains committed to providing high-quality, dependable services to communities across Ireland. We encourage all passengers to book their tickets in advance at to guarantee their seat and ensure a smooth and efficient travel experience.' Join our Dublin Live breaking news service on WhatsApp. Click this link to receive your daily dose of Dublin Live content. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. If you're curious, you can read our Privacy Notice . For all the latest news from Dublin and surrounding areas visit our homepage.
